Amgen's Xgeva delays prostate cancer metastasis

Wednesday, May 18, 2011 12:22 PM

Results from a phase III trial of Amgen's Xgeva have demonstrated that the drug is able to delay the progression of prostate cancer into the bone, which could increase its market potential, according to Pharma Times.

Data showed that Xgeva (denosumab), which is also marketed as Prolia for the treatment of osteoporosis, significantly improved the median bone metastasis-free survival by 4.2 months, a risk reduction of 15%, compared to placebo.

While no survival benefits were noted, the Xgeva study is reportedly the first randomized trial to show a significant reduction in the risk of bone metastasis for men with prostate cancer.  

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs